|
Fulgent Genetics Inc (NASDAQ: FLGT) |
|
Fulgent Genetics Inc
FLGT's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Fulgent Genetics Inc 's sales fell
by -15.59 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2276
Medical Laboratories industry recorded
growth of revenues by 6.58 %
Fulgent Genetics Inc net loss increased from $-13 millions, to $-15 millions in III. Quarter 2024,
• More on FLGT's Growth
|
|
Fulgent Genetics Inc realized a net loss in trailing twelve months.
Fulgent Genetics Inc realized cash reduction of $ -0.85 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 1.85.
Medical Laboratories industry's Price to Sales ratio is at 2.65.
• More on FLGT's Valuation
|
|
|
|
|
Fulgent Genetics Inc realized net loss in trailing twelve months.
Fulgent Genetics Inc realized cash outflow of $ -0.85per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 1.85.
Medical Laboratories industry's Price to Sales ratio is at 2.65.
Fulgent Genetics Inc Price to Book Ratio is at 0.45 lower than Industry Avg. of 30.28. and higher than S&P 500 Avg. of 0.01
• More on FLGT's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com